Navigation Links
Turning on cell-cell communication wipes out staph biofilms
Date:4/30/2008

ntities of the pure AIPs, which allowed the team to conduct biofilm dispersal experiments.

"Figuring out how to synthesize these signal molecules so that we could do the dispersal experiments was a real breakthrough," he said. "We used this new method to make AIP, added it directly to established biofilms and watched them blow apart. And that's when the excitement started."

Having established that activation of the quorum-sensing system in established biofilms triggers dispersal of the biofilm, the UI team has started to investigate the details of the mechanism. In particular, they discovered the mechanism depended on the presence of active proteases -- enzymes that break down proteins.

"If we can learn more about how the system works, then that might suggest new therapeutic targets," said Blaise Boles, Ph.D., UI postdoctoral research fellow.

Importantly, Horswill and Boles also showed that bacteria released from the biofilm were once again susceptible to antibiotics, which raises possibilities for improving treatments for chronic biofilm infections.

"Current treatment for endocarditis -- a potentially life threatening infection where a staph biofilm forms on heart valves -- involves weeks of intravenous antibiotics, and sometimes requires surgery," Boles explained. "One thing we'd like to test is whether we can treat biofilms in models of diseases like endocarditis by turning on quorum sensing."

Horswill added that he plans to start a collaborative effort with Jose Morcuende, M.D., Ph.D., UI associate professor of orthopaedics and rehabilitation, to investigate the dispersal of staph biofilms from both allograft bone and medical implant materials.

The findings also may have implications for treating biofilms of emerging antibiotic resistant staph strains, including methicillin-resistant Staphylococcus aureus (MRSA).

Although the team has not tested their dispersal methods on MSRA, Horswill note
'/>"/>

Contact: Jennifer Brown
jennifer-l-brown@uiowa.edu
319-335-9917
University of Iowa
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Cow stomach holds key to turning corn into biofuel
2. Montana State University researcher finds renewed interest in turning algae into fuel
3. Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results
4. Scripps research team blocks bacterial communication system to prevent deadly staph infections
5. 2 French scientists win European award for communication
6. Springer book wins Quality of Communication Award
7. Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results
8. A private bandwidth for communication in bats: Evidence from insular horseshoe bats
9. Best treatment identified to reduce deadly Staph infections
10. Microbial biofilms evoke Jekyll & Hyde effects
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2